Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Genzyme Threatened As Shire’s Treatment Moves Closer To Market

By Pharmaceutical Processing | August 3, 2009

NEW YORK (AP) — Shares of Genzyme Corp. fell further Monday as potential rival Shire Plc. moved closer to putting a genetic disorder treatment on the market. The competitive threat comes on the heels of Friday’s announcement that the Food and Drug Administration will re-inspect a Boston facility to determine whether certain manufacturing issues are resolved. The stock fell $1.72, or 3.3 percent, to $50.17 in afternoon trading, and fell as low as $49.84 earlier in the trading session, marking its lowest point in about five years. On Friday, shares slid 7 percent following the announcement of the FDA inspection. On Monday, U.K.-based Shire said its Gaucher disease treatment met key goals in a late-stage study. Gaucher disease is an enzyme disorder that can result in liver and neurological problems. If Shire’s velaglucerase is approved, it would compete directly with Genzyme’s Cerezyme. Meanwhile, the FDA accepted Shire’s treatment protocol for the drug, which means physicians can treat patients with the drug prior to traditional FDA approval. The company is asking for approval of the drug using a “rolling submission,” which allows it to submit study findings on an ongoing basis. Shire expects the submissions to be complete by the end of the quarter. The potential threat to Genzyme’s Cerezyme comes as the FDA plans to reinspect the company’s Boston facility to determine whether manufacturing problems discovered in February have been fixed. The company said it fixed the problems and the plant was re-inspected by the agency in May. Meanwhile, the company had to temporarily shut down the production facility in June to clean up viral contamination that had been slowing down the process for making supplies of two biotech-based drugs. The virus, which is not harmful to people, was detected in a bioreactor at the facility. Bioreactors are used in the production of living cells, which are in turn used to make the biotech-based drugs Cerezyme and Fabrazyme. Fabrazyme treats an inherited disorder known as Fabry disease, which is caused by the buildup of a particular type of fat in the body’s cells.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE